Figure 1

Oral fat load test in healthy volunteers and two carriers of dominant negative loss-of-function double mutation R104C/V114A. These subject were previously shown to have no or reduced plasma PCSK9 (22). (A) Plasma TG and (B) plasma PCSK9 concentrations were determined at various time points after the oral fat load. For the subject 1, plasma PCSK9 was undetectable all through the test. Data represent means ± SEM.